Compare TG Therapeutics Inc (TGTX) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs US Bancorp — how do they compare? TG Therapeutics Inc trades at $49.59 (market cap $7.64B), while US Bancorp trades at $64.8 (market cap $100.17B). The key difference: US Bancorp is far larger — about 13.1× TG Therapeutics Inc's market cap, and US Bancorp pays a 3.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | USB | |
|---|---|---|
Market Cap | $7.64B | $100.17B |
Sector | Health | Financials |
52-Week High | $59.06 | $64.47 |
52-Week Low | $26.94 | $45.28 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
U.S. Bancorp (USB) trades at $64.80, up 0.95% today, with a bullish technical trend and strong support at $64. The company reported Q2 2026 EPS of $1.35, beating estimates, and maintains a net income margin of 27.61%. Recent news highlights institutional buying and upbeat Q2 results, reinforcing positive sentiment.
The outlook is positive with a consensus price target of $70.27, indicating potential upside. Risks include rising interest rate sensitivity and competitive pressures. Earnings growth and dividend stability support a favorable investment case, though macroeconomic factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
